These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 1750062

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR.
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal transplantation. Effect of duration of ALG therapy.
    Stratta RJ, D'Alessandro AM, Armbrust MJ, Pirsch JD, Sollinger HW, Kalayoglu M, Belzer FO.
    Transplantation; 1989 Jan; 47(1):96-102. PubMed ID: 2643236
    [Abstract] [Full Text] [Related]

  • 7. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 8. Individualization of immediate posttransplant immunosuppression. The value of antilymphocyte globulin in patients with delayed graft function.
    Matas AJ, Tellis VA, Quinn TA, Glicklich D, Soberman R, Veith FJ.
    Transplantation; 1988 Feb; 45(2):406-9. PubMed ID: 3278434
    [Abstract] [Full Text] [Related]

  • 9. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 10. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation. Results of a randomized prospective study.
    Novick AC, Hwei HH, Steinmuller D, Streem SB, Cunningham RJ, Steinhilber D, Goormastic M, Buszta C.
    Transplantation; 1986 Aug; 42(2):154-8. PubMed ID: 3526655
    [Abstract] [Full Text] [Related]

  • 11. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
    Lum CT, Umen AJ, Kasiske B, Goerdt P, Heim-Duthoy KL, Andersen RC, Odland MD, Ney AL, Jacobs DM, Rao KV.
    Transplantation; 1995 Feb 15; 59(3):371-6. PubMed ID: 7871567
    [Abstract] [Full Text] [Related]

  • 12. Sequential antilymphoblast globulin and cyclosporine for renal transplantation.
    Sommer BG, Henry M, Ferguson RM.
    Transplantation; 1987 Jan 15; 43(1):85-90. PubMed ID: 3541330
    [Abstract] [Full Text] [Related]

  • 13. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE, Gohh R, Shaffer D, Crosson A, Madras PN, Sahyoun AI, Monaco AP.
    Transplantation; 1997 Mar 27; 63(6):845-8. PubMed ID: 9089224
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A randomized trial comparing cyclosporine with antilymphoblast-globulin-azathioprine for renal allograft recipients. Results at 2 1/2-6 years.
    Johnson CP, Simmons RL, Sutherland DE, Canafax DM, Ascher NL, Payne WD, Flick B, Najarian JS, Fryd DS.
    Transplantation; 1988 Feb 27; 45(2):380-5. PubMed ID: 3278431
    [Abstract] [Full Text] [Related]

  • 16. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function.
    Waiser J, Slowinski T, Brinker-Paschke A, Budde K, Schreiber M, Böhler T, Hauser I, Neumayer HH.
    Nephrol Dial Transplant; 2002 Jul 27; 17(7):1310-7. PubMed ID: 12105257
    [Abstract] [Full Text] [Related]

  • 17. Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation.
    Griño JM, Alsina J, Sabater R, Castelao AM, Gil-Vernet S, Andres E, Sabate I, Mestre M, Seron D, Diaz C.
    Transplantation; 1990 Jun 27; 49(6):1114-7. PubMed ID: 2360253
    [Abstract] [Full Text] [Related]

  • 18. Detrimental effects of cyclosporin A on long-term graft survival in familial Mediterranean fever renal allograft recipients: experience of two transplantation centers.
    Shabtai M, Ben-Haim M, Zemer D, Malinger-Saavedra P, Rosin D, Kuriansky J, Lustig S, Shabtai EL, Shapira Z, Ayalon A.
    Isr Med Assoc J; 2002 Nov 27; 4(11 Suppl):935-9. PubMed ID: 12455184
    [Abstract] [Full Text] [Related]

  • 19. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW, Jendrisak MD, So SK, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T.
    Transplantation; 1994 Feb 27; 57(3):377-84. PubMed ID: 8108873
    [Abstract] [Full Text] [Related]

  • 20. A comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients.
    Michael HJ, Francos GC, Burke JF, Besarab A, Moritz M, Gillum D, Jarrell B.
    Transplantation; 1989 Nov 27; 48(5):805-8. PubMed ID: 2683263
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.